The Global Opioid-Induced Constipation OIC Drug Market size is forecast to grow from USD 3.1 billion in 2019 to USD 4.5 billion by 2028, at a CAGR of 6.2% during the forecast period (2021-2028). Global market growth is primarily driven by the rising prevalence of chronic pain and opioid addiction due to increased usage or abuse of prescription opioids with an increased risk for constipation as a side effect. Other factors driving this market include technological advancements in formulary development, increasing expenditure on chronic pain management therapies, and an increase in demand for non-opioid drugs (e.g., Lubiprostone) used for the treatment of constipation caused by opioid use disorder are also contributing to the growth of this market over the forecast period.
Opioid-Induced Constipation OIC Drugs helps in treating the problems related to bowel movements when opioids such as morphine, codeine, and hydrocodone are taken for pain relief or cough suppression.
On the basis of Types, the market is segmented into Lubiprostone, Methyl Naltrexone Bromide, Naldemedine, Alvimopan, and Other.
Lubiprostone can be defined as a small molecule drug that is approved for the treatment of chronic idiopathic constipation and to increase the frequency in patients with opioid-induced bowel dysfunction (OIBD). The clinical efficacy of Lubiprostone has been demonstrated by its ability to treat chronic idiopathic constipation, which is a condition characterized by the less frequent passage of stool than normal.
Lubiprostone is a drug that can be used to treat chronic constipation. It works by causing the muscles in the intestines to contract, thereby speeding the passage of stool through the gut.
Methyl Naltrexone Bromide is an opioid antagonist that belongs to the benzomorphan family of drugs. It works by blocking opiate receptors in the brain and gastrointestinal tract, thereby reducing constipation.
Methyl Naltrexone Bromide is used to treat opioid-induced constipation (OIC) in adults who are taking long-term opioids for the treatment of chronic pain. It can also be given as a single dose before surgery, or after an overdose, when bowel function may be slowed down due to using other drugs that could cause constipation and affect recovery from anesthesia.
Naldemedine is an opioid antagonist used to treat opioid-induced constipation. It binds to the mu receptor and blocks signals for pain relief in those receptors, which can cause a laxative effect. Naldemedine blocks opiate receptors in the intestine and can relieve uncomfortable digestive tract symptoms caused by the long-term use of opioids without disrupting pleasurable effects like pain relief from these medications.
Alvimopan is a medication that treats opioid-induced constipation (OIC) by decreasing the amount of time it takes for food to move through your digestive system. It does this by acting on receptors in the intestines and colon, which sends signals telling them when contract. This helps increase peristalsis, or muscle movement, so bowel movements will be more frequent after taking Alvimopan.
On the basis of Application, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online pharmacies. In hospitals, Opioid-Induced Constipation OIC Drugs are used by healthcare practitioners for treating constipation in patients who have been taking opioids. Medical professionals give these drugs to reduce the risks of opioid withdrawal symptoms and discomfort that are associated with chronic use or abrupt discontinuation of opioids.
On the basis of Region, the market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. The Latin American region has been witnessing high demand for opioids due to the increased number of opioid-induced constipation OICs launches. The popularity of such products is largely attributed to their ability to provide relief from chronic pain associated with diseases like cancer or HIV/AIDS etc., which also results in better uptake at retail pharmacies.
The global opioid-induced constipation OIC market is influenced by various factors. The growth of the world population, which has led to an increase in chronic diseases and noncommunicable diseases (NCDs), will contribute significantly towards driving this market. This includes a rise in cancer cases globally, where patients are more likely develop severe bouts of diarrhea due to opioids.
Oncology drugs have also been used for treatment-related side effects such as nausea and vomiting; however, these can cause constipation among other things when not administered properly. Despite its associations with pain relief, there are some instances where individuals may be prescribed a combination of opioids and narcotics manage their adverse reactions from chemotherapy or post-surgical complications like acute bowel obstruction that leads them to develop opioid-induced constipation.
Up Market Research published a new report titled “Opioid Induced Constipation OIC Drug Market research report which is segmented by Types (Lubiprostone, Methyl Naltrexone Bromide, Naldemedine, Alvimopan, Other), By Applications (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Players/Companies Ironwood Pharmaceuticals, Daiichi Sankyo Co, Pfizer, Progenics Pharmaceuticals, Shionogi &, Allergan, Nektar Therapeutics, Purdue Pharma, S.L.A. Pharma, Mundipharma International Limited, Ono Pharmaceutical, Takeda Pharmaceutical Company Limited, Theravance Biopharma, Bausch Health, Cosmo Pharmaceuticals SA, Daewoong Pharmaceutical, C.B. Fleet Company, Sucampo Pharmaceuticals”.
|Report Attributes||Report Details|
|Report Title||Opioid Induced Constipation OIC Drug Market Research Report|
|By Type||Lubiprostone, Methyl Naltrexone Bromide, Naldemedine, Alvimopan, Other|
|By Application||Hospital Pharmacies, Retail Pharmacies, Online Pharmacies|
|By Companies||Ironwood Pharmaceuticals, Daiichi Sankyo Co, Pfizer, Progenics Pharmaceuticals, Shionogi &, Allergan, Nektar Therapeutics, Purdue Pharma, S.L.A. Pharma, Mundipharma International Limited, Ono Pharmaceutical, Takeda Pharmaceutical Company Limited, Theravance Biopharma, Bausch Health, Cosmo Pharmaceuticals SA, Daewoong Pharmaceutical, C.B. Fleet Company, Sucampo Pharmaceuticals|
|Regions Covered||North America, Europe, APAC, Latin America, MEA|
|Historical Year||2018 to 2019 (Data from 2010 can be provided as per availability)|
|Number of Pages||220|
|Number of Tables & Figures||154|
|Customization Available||Yes, the report can be customized as per your need.|
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
The market is segmented by Type Lubiprostone, Methyl Naltrexone Bromide, Naldemedine, Alvimopan, Other and By Application Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Some of the companies that are profiled in this report are:
Opioid Induced Constipation OIC Drug Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
We have studied the Opioid Induced Constipation OIC Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
Reasons to Purchase the Opioid Induced Constipation OIC Drug Market Report:
Some other reports from this category!